J. Sculier (Brussels, Belgium), E. Quoix (Strasbourg, France)
Palliative chemotherapy in non-small cell lung cancer (NSCLC): analysis of UK baseline data from the ACTION observational study P. Mehta, J. Watkins, M. Watt, C. P. Schneider, S. Knowles, S. Bhalla (Hampshire, United Kingdom; Bad Berka, Germany)
| |
Evaluation by immunohistochemistry of EGF-R expression before and after chemotherapy in non small cell lung cancer P. Lothaire, B. Martin, A. P. Meert, V. Ninane, J. P. Sculier (Brussels, Belgium)
| |
Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer M. Pesek, L. Benesova, M. Jelinkova, F. Bruha, P. Mukensnabl (Plzen, Prague, Czech Republic)
| |
Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study G. Buccheri, D. Ferrigno (Cuneo, Italy)
| |
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study L. C. Herve, C. Christos, J. Herve, V. Alain (Draguignan, Paris, Martigues, Limoges, France)
| |
Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer S. Ohsugi, Y. Iwasaki, T. Yamada, T. Yamada, T. Yuba, K. Kohno, I. Hasegawa, S. Hosogi, H. Kuwahara, K. Nagata, I. Yokomura (Kyoto, Japan)
| |
Aerosol delivery of chemotherapy in an orthotopic model of lung cancer F. Gagnadoux, A. Le Pape, E. Lemarié, S. Lerondel, I. Valo, V. Leblond, J. L. Racineux, T. Urban (Angers, Orléans, Tours, France)
| |
Palliative chemotherapy in non-small cell lung cancer (NSCLC): first-line therapy data from the ACTION observational study H. Bischoff, M. Thomas, M. Leschinger, R. Bonnet, C. Steppert, J. Fischer, H. Bolouri, E. Mueller (Heidelberg, Munster, Bad Homburg, Bad Berka, Ebensfeld, Lowenstein, Hamburg, Germany)
| |